Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a ...

As previously reported, Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target The firm views ...

Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target Stay Ahead of the Market: Discover ...

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) gapped up before the market opened on Friday . The stock ...

Wellington Management Group LLP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.5% during the fourth quarter, Holdings Channel.com reports.

WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

Investors considering a purchase of Spyre Therapeutics Inc (Symbol: SYRE) stock, but cautious about paying the going market price of $18.16/share, might benefit from considering selling puts among ...

About Spyre Therapeutics Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining ...